Literature DB >> 10196379

Germline BRCA1 alterations in a population-based series of ovarian cancer cases.

S A Janezic1, A Ziogas, L M Krumroy, M Krasner, S J Plummer, P Cohen, M Gildea, D Barker, R Haile, G Casey, H Anton-Culver.   

Abstract

The objective of this study was to provide more accurate frequency estimates of breast cancer susceptibility gene 1 ( BRCA1 ) germline alterations in the ovarian cancer population. To achieve this, we determined the prevalence of BRCA1 alterations in a population-based series of consecutive ovarian cancer cases. This is the first population-based ovarian cancer study reporting BRCA1 alterations derived from a comprehensive screen of the entire coding region. One hundred and seven ovarian cancer cases were analyzed for BRCA1 alterations using the RNase mismatch cleavage assay followed by direct sequencing. Two truncating mutations, 962del4 and 3600del11, were identified. Both patients had a family history of breast or ovarian cancer. Several novel as well as previously reported uncharacterized variants were also identified, some of which were associated with a family history of cancer. The frequency distribution of common polymorphisms was determined in the 91 Caucasian cancer cases in this series and 24 sister controls using allele-specific amplification. The rare form of the Q356R polymorphism was significantly ( P = 0.03) associated with a family history of ovarian cancer, suggesting that this polymorphism may influence ovarian cancer risk. In summary, our data suggest a role for some uncharacterized variants and rare forms of polymorphisms in determining ovarian cancer risk, and highlight the necessity to screen for missense alterations as well as truncating mutations in this population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196379     DOI: 10.1093/hmg/8.5.889

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  16 in total

1.  Functional single-nucleotide polymorphisms in the BRCA1 gene and risk of salivary gland carcinoma.

Authors:  Li Xu; Phi C Doan; Qingyi Wei; Guojun Li; Erich M Sturgis
Journal:  Oral Oncol       Date:  2012-04-12       Impact factor: 5.337

Review 2.  Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  David J Hughes
Journal:  Fam Cancer       Date:  2008-02-19       Impact factor: 2.375

3.  Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

Authors:  Susan A J Vaziri; Dale R Grabowski; Jason Hill; Lisa R Rybicki; Robert Burk; Ronald M Bukowski; Mahrukh K Ganapathi; Ram Ganapathi
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

4.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.

Authors:  S A Vaziri; R R Tubbs; G Darlington; G Casey
Journal:  Mol Pathol       Date:  2001-08

5.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Authors:  R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod
Journal:  Am J Hum Genet       Date:  2000-03-16       Impact factor: 11.025

6.  Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma.

Authors:  Li Xu; Phi C Doan; Qingyi Wei; Yanhong Liu; Guojun Li; Erich M Sturgis
Journal:  Thyroid       Date:  2011-12-02       Impact factor: 6.568

7.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Authors:  H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02-15       Impact factor: 11.025

8.  Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.

Authors:  Sean P Cleary; Hyeja Kim; Marina E Croitoru; Mark Redston; Julia A Knight; Steven Gallinger; Robert Gryfe
Journal:  Dis Colon Rectum       Date:  2008-07-10       Impact factor: 4.585

9.  Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.

Authors:  Desislava Dimitrova; Ilary Ruscito; Sven Olek; Rolf Richter; Alexander Hellwag; Ivana Türbachova; Hannah Woopen; Udo Baron; Elena Ioana Braicu; Jalid Sehouli
Journal:  Tumour Biol       Date:  2016-06-14

10.  Common variation in the BRCA1 gene and prostate cancer risk.

Authors:  Julie A Douglas; Albert M Levin; Kimberly A Zuhlke; Anna M Ray; Gregory R Johnson; Ethan M Lange; David P Wood; Kathleen A Cooney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06-21       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.